CRL earnings call summary

Prepared Highlights

• Revenue: Q2 2025 revenue of $1.03B, +0.6% YoY; organic revenue -0.5% (prepared).
• DSA segment: Revenue $618M, organic -2.4% YoY; backlog $1.93B (down from $1.99B Q1); net book-to-bill 0.82x (Q2), first-half 0.93x (prepared).
• DSA bookings: Gross and net bookings both +mid-single-digit YoY in Q2; first-half gross bookings +6%, net bookings +13% (CEO).
• RMS segment: Revenue $213.3M, organic +2.3% YoY; operating margin 25.3% (+220bps YoY) (CEO).
• Manufacturing segment: Revenue $200.8M, organic +2.9% YoY; operating margin 32.8% (+620bps YoY) (CEO).
• Operating margin: Consolidated 22.1% (+80bps YoY); full-year expected flat to -30bps (CFO).
• CapEx: Q2 $35.3M (~3% of revenue); full-year ~$230M (CFO).
• Free cash flow: Q2 $169.3M (up from $154M YoY); full-year raised to $430M–$470M (CFO).
• Cost savings: On track for >$175M run rate in 2025, ~$225M in 2026 (CFO).
• NHP supply: DOJ no longer investigating Cambodia shipments; all shipments cleared for legal entry (CEO).

Official Guidance

• Full-year 2025: Reported revenue -0.5% to -2.5%; organic revenue -1% to -3%; non-GAAP EPS $9.90–$10.30 (raised $0.55 at midpoint) (CFO).
• Segment organic revenue: DSA low-to-mid-single-digit decline (improved from mid-single-digit); RMS flat to slightly positive; Manufacturing essentially flat (CFO).
• Q3 2025: Reported and organic revenue -2% to -4% YoY; non-GAAP EPS decline low-double-digit YoY (CFO).
• Tax rate: Full-year non-GAAP 23.5%–24.5% (+100bps); Q3 elevated 25%–30% (CFO).
• Interest expense: Full-year $100M–$105M (CFO).

Mgmt Quotes

• "We reported another solid financial performance in the second quarter, meaningfully exceeding our prior outlook due primarily to favorable DSA results." (CEO)
• "We never expected a straight-line recovery in the net book-to-bill or broader DSA demand trends." (CEO)
• "The strategic review is well underway, and I am encouraged by the progress that we have made so far." (CEO)
• "Free cash flow for the second quarter remained strong at $169.3 million, an increase from $154 million last year." (CFO)
• "Our restructuring program... is on track to deliver annualized cost savings of over $175 million in 2025 and approximately $225 million in 2026." (CFO)

Prepared Metrics

Q&A Batch (1-5 of 9)

Q1 — Elizabeth Hammell Anderson

• Topic: 当前需求环境与下半年指引
• Key points:
  • 制药客户需求稳定且改善，收入连续三季同比小幅增长；生物技术分化，小企业仍受资金限制，中型生物技术表现较好
  • 净book-to-bill过去18个月呈稳定上升趋势，上半年在0.8x–0.93x区间
  • 下半年指引不依赖book-to-bill回到1x以上，维持当前区间即可
• Mgmt stance: 谨慎看多——制药端明确回暖，但政府不确定性和资本获取仍构成风险，管理层对全年指引有信心

Q2 — Eric White Coldwell

• Topic: CDMO业务与柬埔寨NHP解禁影响
• Key points:
  • CDMO上半年有2,000万美元收入来自单一客户（风停项目），该收入毛利率高于正常水平，且Q2包含一笔未量化的额外付款
  • 该客户收入成为下半年逆风（不再生产），管理层一季度已预警约4,000万美元头风，现略低于500bps
  • 美国鱼类和野生动物管理局解禁柬埔寨NHP，增加动物来源灵活性，有助于下半年及未来规划
• Mgmt stance: 看多——NHP解禁消除监管不确定性，CDMO高毛利收入虽暂时提振但已被充分纳入指引

Q3 — David Howard Windley

• Topic: CDMO头风具体计算与DSA收入转换能力
• Key points:
  • 针对单一CDMO客户：全年头风约38-39百万美元（去年基数约60百万美元），上半年已确认20百万美元，下半年为零
  • DSA backlog约10个月，转化率因取消长期研究而略有加速；取消主要集中于后期/大额研究，但能由其他类型研究补充
  • 目前实际运营表现超过计划，已开始招聘以保障交付能力
• Mgmt stance: 中性偏积极——backlog稳健，制药端需求增强，但取消率难以预测，需观察资本开放

Q4 — Patrick Bernard Donnelly

• Topic: 招聘信号与定价对利润率的影响
• Key points:
  • 招聘是为匹配当前活动水平，并非提前预期拐点；book-to-bill维持在0.9x左右是否支持明年DSA增长未给出明确判断
  • DSA定价稳定，spot定价靠科学和质量竞争，仅偶尔用价格工具；上半年mix有利推高价格，但公司不假设mix持续
  • 利润率受定价、mix和招聘共同影响，下半年mix可能回归正常
• Mgmt stance: 中性——不超前于需求招聘，定价稳定但mix不确定性需关注

Q5 — Casey Rene Woodring

• Topic: 高取消率原因与政府政策潜在影响
• Key points:
  • 取消集中在后期/大额研究，源于客户组合优先级调整，非趋势性恶化；利润率差异不大
  • 政府对药品定价（MFN）、NIH/FDA的不确定性和关税目前对公司“微乎其微”的影响，但学术客户已出现少量NIH项目取消
  • 指引已假设环境更严峻，若政策落地，对2026年影响可能大于2025下半年
• Mgmt stance: 谨慎——取消是暂时现象，政策风险已纳入指引，但2026年影响需观察

Q&A Batch (6–9 of 9)

Q6 — Charles Rhyee

• Topic: H2 margin headwinds (DSA hiring, CDMO normalization, merit timing)
• Key points:
  • DSA headwind from extra hiring (temporary, ramp-up ahead of demand); CDMO Q2 margins were elevated and will normalize in H2.
  • Merit increase effective July 1 adds ~3.5% to salary/labor cost base in H2 vs H1.
  • DOJ conclusion: legal expenses and NHP inventory write-off were non-GAAP; going forward, NHPs expensed as normal cost when studies run.
• Mgmt stance: Neutral — confirms analyst’s view; no additional headwinds beyond those cited.

Q7 — Maxwell Andrew Smock

• Topic: DSA outperformance drivers and headcount growth outlook
• Key points:
  • DSA beat driven by strong Q1 bookings (pent-up demand, clients moving quickly, positive price mix) plus ~half of beat from FX.
  • Q2 change orders and slippage were better than expected, contributing to the beat.
  • Headcount: not up year-over-year (revenue still declining), but up vs beginning of year; ~$10M H2 margin headwind from hiring timing.
• Mgmt stance: Cautiously optimistic — demand stabilizing, especially in pharma; headcount added carefully to match demand.

Q8 — Joshua Paul Waldman

• Topic: DSA visibility, cancellations, and guide assumptions
• Key points:
  • Visibility improving as clients emerge from cautious period; cancellations remain difficult to predict.
  • Q2 cancellation rate (% of bookings) similar to last 18 months; Q1 was unusually favorable.
  • Post-IND cancellations driven by large complex studies (different clients, different reasons); general toxicology work strengthened in Q2.
• Mgmt stance: Neutral — better clarity but not overreading; guidance built cautiously; 2026 plans will be clearer as clients set operating plans.

Q9 — Unidentified Analyst (Anna Krasinski)

• Topic: DSA sales cycle timing (RFP to award to revenue)
• Key points:
  • Sales cycle length has not changed; structural changes (client-centric sales, discovery-to-safety focus) have improved process.
  • Speed of study execution and reporting is critical for clients; digitization and sales force amalgamation have enhanced cycle.
• Mgmt stance: Bullish — cycle is “somewhat improved and enhanced” vs last year; more focused and elegant.